NAF has launched a petition on Change.org calling on the FDA to prioritize treatment options for rare diseases with urgent unmet needs, including Spinocerebellar Ataxia (SCA).
SIGN THE PETITION
After an extensive national search with many highly qualified candidates, we are excited to announce NAF’s very first Chief Scientific Officer! We’d like to extend a warm welcome to Lauren Moore, PhD. She stood out for her outstanding scientific knowledge, passion for serving the Ataxia community, and commitment to NAF’s Read More…
You know that we ask for your donations to help us fund more Ataxia research. You know that research grants are only possible because of generous gifts from people like you. You know that research is the key to finding effective treatments and a cure. But do you know why Read More…
We want to tell you about an opportunity to participate in research that can improve clinical care for Ataxia! Did You Know? NAF actively recruits research participants for the natural history study on Ataxia, which is run by the Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA). Their mission is Read More…
NAF is proud to feature Felicia Williams as a recipient of NAF’s 2020 Diverse Scientists in Ataxia Pre-Doctoral Research Fellowship. Felicia developed a new method to identify genes that suppress protein clumping. Bio: Felicia Williams graduated from the University of Georgia in 2019 where she studied genetics and biotechnology. Here Read More…
Let’s chat about Clinical Trial Readiness with a focus on Ataxia. Clinical trials ensure that treatments are safe and effective before they gain approval for widespread use in humans. Clinical trials test new treatments and therapies including: new drugs, different use for an already approved drug, medical devices, new treatment/therapy Read More…
What does a placebo mean? A placebo is a simulated substance that has no therapeutic effect or active ingredients. Often, a placebo looks, feels, and tastes like other therapies being tested in the clinical trial. What is the placebo effect, and why is it important? https://www.youtube.com/watch?v=5RhG_ySxhDA Why are placebo-controlled trials Read More…
Author: Sue Hagen, Research Services Director I recently attended the virtual annual meeting of the Drug Information Association. I took in four days of sessions, all relating to topics of interest to all stakeholders involved in drug discovery and development. My head is still spinning! While you would think that Read More…
What is an Informed Consent Form (ICF)? Informed Consent Forms are important aspect of a clinical trial. An ICF is a document that provides a potential clinical trial participant information about the clinical trial and any risks there may be in participating. The goal behind the ICF is to present Read More…
NAF is committed to providing the resources to fund research needed to develop treatments and therapies for people with Ataxia. We fund research studies ranging from $35,000-$100,000 per study. We are accepting Letters of Intent for research grants through late September and early October on proposalCENTRAL. For more information visit www.ataxia.org/researcher-resources. If you Read More…
Guest Authors: Drs. Paulson, Ashizawa, and Öz Right now, it’s an exciting time in the Ataxia field. Many companies are working rapidly to bring therapies to the clinic for the Spinocerebellar Ataxias (SCAs). Unfortunately, however, we still need to know more about the natural history of SCA and relevant biomarkers Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
